These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9397424)

  • 1. Effects of the 5-HT3 antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia.
    McCann UD; Morgan CM; Geraci M; Slate SO; Murphy DL; Post RM
    Neuropsychopharmacology; 1997 Dec; 17(6):360-9. PubMed ID: 9397424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the effects of intravenous pentagastrin on patients with social phobia, panic disorder and healthy controls.
    McCann UD; Slate SO; Geraci M; Roscow-Terrill D; Uhde TW
    Neuropsychopharmacology; 1997 Mar; 16(3):229-37. PubMed ID: 9138439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive modulation of the endocrine stress response to a pharmacological challenge in normal and panic disorder subjects.
    Abelson JL; Liberzon I; Young EA; Khan S
    Arch Gen Psychiatry; 2005 Jun; 62(6):668-75. PubMed ID: 15939844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pentagastrin-induced sleep panic attacks: panic in the absence of elevated baseline arousal.
    Geraci M; Anderson TS; Slate-Cothren S; Post RM; McCann UD
    Biol Psychiatry; 2002 Dec; 52(12):1183-9. PubMed ID: 12488064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptides and anxiety: a dose-response evaluation of pentagastrin in healthy volunteers.
    McCann UD; Slate SO; Geraci M; Uhde TW
    Anxiety; 1994-1995; 1(6):258-67. PubMed ID: 9160584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans.
    Dépôt M; Caillé G; Mukherjee J; Katzman MA; Cadieux A; Bradwejn J
    Neuropsychopharmacology; 1999 Feb; 20(2):177-87. PubMed ID: 9885797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients.
    van Megen HJ; Westenberg HG; den Boer JA; Haigh JR; Traub M
    Psychopharmacology (Berl); 1994 Apr; 114(3):449-55. PubMed ID: 7855203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flumazenil challenge in social phobia.
    Coupland NJ; Bell C; Potokar JP; Dorkins E; Nutt DJ
    Depress Anxiety; 2000; 11(1):27-30. PubMed ID: 10723632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anxiety sensitivity in social phobia: comparison between social phobics with and without panic attacks.
    Scott EL; Heimberg RG; Jack MS
    Depress Anxiety; 2000; 12(4):189-92. PubMed ID: 11195754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose response of adrenocorticotropin and cortisol to the CCK-B agonist pentagastrin.
    Abelson JL; Liberzon I
    Neuropsychopharmacology; 1999 Oct; 21(4):485-94. PubMed ID: 10481831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of central administration of the CCK-B receptor agonist pentagastrin on feeding and cortisol release in sheep.
    Ebenezer IS; Parrott RF
    Methods Find Exp Clin Pharmacol; 1996 May; 18(4):235-8. PubMed ID: 8803955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral, physiological and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment.
    Broocks A; Briggs NC; Pigott TA; Hill JL; Canter SK; Tolliver TJ; Baldemore D; Murphy DL
    Psychopharmacology (Berl); 1997 Mar; 130(2):91-103. PubMed ID: 9106905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of patients with illness phobia and panic disorder.
    Noyes R; Wesner RB; Fisher MM
    Psychosomatics; 1992; 33(1):92-9. PubMed ID: 1539109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anxiogenic effects of pentagastrin in patients with social phobia and healthy controls.
    van Vliet IM; Westenberg HG; Slaap BR; den Boer JA; Ho Pian KL
    Biol Psychiatry; 1997 Jul; 42(1):76-8. PubMed ID: 9193745
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of repeat exposure on neuroendocrine and symptom responses to pentagastrin.
    Khan S; Liberzon I; Abelson JL
    Psychiatry Res; 2004 May; 126(3):189-95. PubMed ID: 15157745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological and behavioral responses to D-amphetamine, alone and in combination with the serotonin3 receptor antagonist ondansetron, in healthy volunteers.
    Grady TA; Broocks A; Canter SK; Pigott TA; Dubbert B; Hill JL; Murphy DL
    Psychiatry Res; 1996 Aug; 64(1):1-10. PubMed ID: 8888359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-schemas in social phobia and panic disorder.
    van Niekerk JK; Möller AT; Nortje C
    Psychol Rep; 1999 Jun; 84(3 Pt 1):843-54. PubMed ID: 10408207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder.
    Ströhle A; Holsboer F; Rupprecht R
    Neuropsychopharmacology; 2000 Mar; 22(3):251-6. PubMed ID: 10693152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects to CCK-4-induced panic by dexamethasone and hydrocortisone.
    Demiralay C; Jahn H; Kellner M; Yassouridis A; Wiedemann K
    World J Biol Psychiatry; 2012 Oct; 13(7):526-34. PubMed ID: 22111662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses.
    Abelson JL; Nesse RM
    Biol Psychiatry; 1994 Jul; 36(2):73-83. PubMed ID: 7948449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.